Notice: No offer or solicitation regarding securities

Contents are provided for general information purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any security of Cloudbreak Pharma, Inc. (“Cloudbreak”) in any jurisdiction. Cloudbreak does not intend to solicit and is not soliciting, any action with respect to its securities. Nothing in this website or the Contents thereof, individually or taken in the aggregate, constitutes an offer of securities for sale or a solicitation of an offer to buy any security in the United States, the United Kingdom, Hong Kong, Singapore, Japan, or in any other jurisdiction in which such an offer or solicitation is unlawful, or to US persons.

The Contents of this section have not been approved or disapproved by any securities commission or regulatory authority in Hong Kong or any other jurisdiction, and Cloudbreak expressly disclaims any duty to make disclosures or any filings with any securities commission or regulatory authority, beyond that imposed by applicable laws. The Contents of this section are not issued pursuant to, and do not constitute, an announcement or disclosure under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. All references to trading relate solely to secondary market transactions conducted through independent intermediaries. The Contents of this section are neither sufficient nor intended by Cloudbreak to be used in connection with any decision relating to the purchase or sale of any existing or future Securities. Therefore, no person should rely on the information contained herein as a basis for any investment or trading decision. Cloudbreak does not, does not intend to, and will not provide financial, investment, tax, legal, or accounting advice. Investors considering the purchase or sale of any Securities should consult with their own independent professional advisors.

The Contents of this section and the certain pages of the website contain information and documents that relate to securities that have not been registered, and will not be registered, for sale in the United States, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, or pledged in or delivered into the United States, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act of 1933 [the “Securities Act”], as amended) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Such securities may also be subject to US tax law requirements. There will be no public offering of the Securities referred to in this section or any other page of the website in the United States. The Contents of this section, information contained in these pages, any opinion expressed therein and Other Contents of this website are provided solely for general information purposes, and do not constitute a sale of, offer for sale of, or solicitation of an offer to buy any securities in any jurisdiction. The Contents of this section is made available on a passive basis and is not directed at any particular jurisdiction or category of investor.

Introduction

Cloudbreak Pharma, Inc. is listed on the Hong Kong Stock Exchange (HKEX).  The ticker symbol is 2592. The shares of Cloudbreak Pharma, Inc. are publicly traded on the secondary market, and investors may acquire or dispose of such shares through licensed or registered intermediaries.

Individuals located outside of Hong Kong typically HKEX-listed securities using international brokerage accounts. For example, in the United States, certain brokerage firms and intermediaries may provide eligible clients with access to securities listed on the Hong Kong Stock Exchange, subject to applicable laws, regulatory requirements and the policies of such intermediaries.  Some examples are below for general reference only.  Cloudbreak does not endorse, recommend or verify any of these methods, and the information is provided solely for informational purposes.

Cloudbreak does not appoint, recommend, or endorse any broker or intermediary. Investors are solely responsible for selecting their own broker and for complying with all applicable laws and regulations in their jurisdiction. Trades may be subject to minimum order sizes or other execution requirements determined by the broker(s)